Syntimmune's Series B Round

Syntimmune raised a round of funding on June 21, 2017. Investors include Apple Tree Partners.

Syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal Fc receptor (FcRn). FcRn is a well-validated target for IgG-mediated autoimmune diseases and repres…

Articles about Syntimmune's Series B Round: